AB
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $2,390M | 0.7% | 2026-06-30 |
| Thomas Russo | Gardner Russo & Quinn | $3M | 0.0% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $3M | 0.0% | 2026-06-30 |
| Dodge & Cox | Dodge & Cox | $3M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Abbvie Inc (ABBV) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for ABBV — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 49.60 | NEUTRAL |
| Stochastic %K (14) | 40.86 | NEUTRAL |
| CCI (20) | -62.64 | NEUTRAL |
| Williams %R (14) | -59.14 | NEUTRAL |
| MACD (12,26,9) | -1.33 | SELL |
| ROC (10) | -3.00 | SELL |
| Momentum (10) | -7.90 | SELL |
| EMA (10) | 255.82 | SELL |
| SMA (10) | 256.31 | SELL |
| EMA (20) | 256.08 | SELL |
| SMA (20) | 257.93 | SELL |
| EMA (30) | 254.84 | BUY |
| SMA (30) | 254.63 | BUY |
| EMA (50) | 250.68 | BUY |
| SMA (50) | 254.07 | BUY |
| EMA (100) | 241.11 | BUY |
| SMA (100) | 234.54 | BUY |
| EMA (200) | 232.27 | BUY |
| SMA (200) | 226.18 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 41 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Peer movement computing — it will appear here on its own.
NEUTRAL 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
